Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
SXTP Stock Chart & Stats
$0.50
-$0.08(-5.71%)
At close: 4:00 PM EST
$0.50
-$0.08(-5.71%)
Day’s Range― - ―
52-Week Range$1.36 - $17.68
Previous CloseN/A
Volume13.44M
Average Volume (3M)199.18K
Market Cap
$3.21M
Enterprise Value-$2.31M
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$153.76K
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Mar 27, 2026EPS Estimate
-2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding1,560,192
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.73
Price to Sales (P/S)4.83
P/FCF Ratio-0.50
Enterprise Value/Market Cap-0.72
Enterprise Value/Revenue-2.40
Enterprise Value/Gross Profit-12.52
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$24.00Price Target Upside4700.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.9
Revenue Forecast (FY)$2.05M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion InitiativesAnalyst highlights company initiatives such as physician outreach, payer and pharmacy engagement, and awareness campaigns that could strengthen prescribing patterns and improve market traction.
Market OpportunityAnalyst points to exploration of additional indications like babesiosis and a sizable addressable market that could materially increase long-term revenue if commercial adoption improves.
Retail And Digital PartnershipsAnalyst notes expanded distribution through GoodRx and telehealth partners increases ARAKODA availability and lowers patient out-of-pocket costs, supporting broader uptake and potential revenue acceleration.
Bears Say
Modest Sales TractionAnalyst warns that ARAKODA sales remain modest, signaling limited current market penetration and a need for stronger commercial execution to drive meaningful growth.
Regulatory And Financing RiskAnalyst cites low visibility on regulatory approval for new indications and the potential for dilutive financing as key risks that could weigh on the stock if outcomes are unfavorable.
Rising Operating ExpensesAnalyst notes elevated operating expenses driven by a new sales and marketing campaign, which could pressure earnings per share if revenue does not keep pace.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.36 and its highest was $17.68 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $3.21M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 19 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
60 Degrees Pharmaceuticals, Inc. released its earnings results on Nov 13, 2025. The company reported -$2.67 earnings per share for the quarter, missing the consensus estimate of -$1.84 by -$0.83.
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -2.28.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 1,560,192 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
60 Degrees Pharmaceuticals, Inc. reported an EPS of -$2.67 in its last earnings report, missing expectations of -$1.84. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
SXTP Stock 12 Month Forecast
Average Price Target
$24.00
▲(4700.00% Upside)
Technical Analysis
Ownership Overview
7.56% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
92.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---